clinical trial · NCT05508867
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Merck Sharp & Dohme LLC·phase2·completed·n = 203
Hodgkin Lymphomafavezelimab/pembrolizumabbendamustinegemcitabine
brief summary
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.
started
Oct 18, 2022
primary completion
Sep 3, 2025
completion
Jan 8, 2026
last updated
Sep 1, 2026
official title
A Phase 2 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol